Figure 1
From: Increased sensitivity of p53-deficient cells to anticancer agents due to loss of Pms2
Antiproliferative effect to a continuous exposure to cisplatin, oxaliplatin, doxorubicin, etoposide, docetaxel, and 5-fluorouracil for Pms2+/+/p53−/− and Pms2−/−/p53−/− cells as determined by the MTT-assay. Each point represents the mean±s.d. of at least four independent experiments.
